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ABSTRACT
Background: Eradication of new infection of
Pseudomonas aeruginosa is an important intervention
in managing cystic fibrosis (CF). Previous trials,
studying predominantly under 18-year-olds, indicate
that antibiotic eradication therapy (AET) has success
rates of 62.8–93.0%. In this retrospective cohort study,
we report the outcomes of AET in an adult population.
Methods: Adults with a confirmed diagnosis of CF
and a first isolation of P aeruginosa were studied
between 1999 and 2012. Choice of therapy, time to
eradication and reinfection, and lung function (forced
expiratory volume in 1 s (FEV1)) were determined.
Results: 20 patients (median age 27 years) isolated
P aeruginosa during the study period. 10 patients were
treated with oral ciprofloxacin (median duration
6 weeks) and nebulised colomycin (median duration
3 months). 7 patients were treated with intravenous
antipseudomonal antibiotics (median duration
14 days). 2 patients received other combinations of
oral and inhaled antipseudomonal therapy and one
patient received no therapy. AET was successful in 15
cases who received antipseudomonal therapy (79%).
The median time to eradication was 1 month. The
median time to reinfection with P aeruginosa was
43 months. There was no significant change in FEV1
after 12 months.
Conclusions: Aggressive AET of new infection of
P aeruginosa in adults is successful in the majority of
patients and has similar efficacy to the reported
efficacy in paediatric populations.
INTRODUCTION
Chronic infection with Pseudomonas aeruginosa
is associated with an adverse prognosis in
adults with cystic ﬁbrosis (CF).1 P aeruginosa
induces a prolonged inﬂammatory response
which leads to progressive pulmonary tissue
destruction. In patients with CF, this manifests
as a more rapid loss of lung function, fre-
quent pulmonary exacerbations and a shorter
median survival.2
Once chronic infection with P aeruginosa is
established, it is rarely possible to eradicate.3
However, the early and intensive use of anti-
biotic eradication therapy (AET) following a
new isolation of P aeruginosa has been shown
to eradicate the pathogen from the respiratory
tract, thus preventing or delaying the establish-
ment of chronic infection.4 Therefore, the
eradication of new P aeruginosa infection is
important in managing patients with CF.
Most studies of P aeruginosa eradication
report median ages in the paediatric range.2
It is not known whether adult patients with
CF who isolate P aeruginosa for the ﬁrst time
have outcomes similar to children. CF
centres are transferring more children to
adult services without chronic P aeruginosa
infection.5 Our aim was to study the efﬁcacy
of AET for ﬁrst P aeruginosa isolation in
adults in order to determine the optimum
management and prognosis of this growing
patient group.
Previous trials report a variety of antipseu-
domonal regimes in predominantly under
18-year-olds with eradication success of 62.8–
93.0%.6–8 We hypothesised that AET for ﬁrst
isolate P aeruginosa would be less effective in
adults compared with children on account of
cumulative pulmonary tissue destruction and
other CF-related disease processes.
METHODS
Study design
This was a retrospective cohort study con-
ducted at the Northern Ireland Regional
Adult Cystic Fibrosis Centre. The study
period was 1 January 1999 until 31
December 2012.
KEY MESSAGES
▸ More patients with cystic fibrosis are being
transferred from paediatric to adult CF services
without a history of chronic P aeruginosa
infection.
▸ Aggressive antibiotic eradication therapy of new
isolation P aeruginosa has similar efficacy in
adults and children with cystic fibrosis.
▸ More evidence is needed to determine the most
efficacious regime of antibiotic eradication
therapy for new isolation P aeruginosa.
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Population demographics
There were 279 patients attending the Northern Ireland
Regional Adult Cystic Fibrosis Centre who were regis-
tered with the UK Cystic Fibrosis Registry database
during the study period. All registered patients met the
current criteria for the diagnosis of CF.9 The median
age of these patients was 30 years. Forty-four per cent
were women and 56% were men. Thirty-six per cent of
patients were homozygous F508del. This was the most
predominant single genetic mutation in this population.
Inclusion/exclusion criteria
Adult patients with CF attending the Northern Ireland
Regional Adult Cystic Fibrosis Centre who isolated
P aeruginosa for the ﬁrst time during the period 1999–
2012 were included in the study. All patients had a diag-
nosis of CF, conﬁrmed by sweat test and genetics.
Patients who died during the study period were
included. Patients who received P aeruginosa eradication
at another centre were not included.
Data collection
The Cystic Fibrosis Registry database was used to obtain
background demographics and results of genetic testing
of the patients with CF registered to this centre. A chart
review was performed including all bacteriology results
from the respiratory cultures (including sputum and
throat swabs) of the cases studied. Paediatric bacteriology
records were used to conﬁrm that P aeruginosa had not
been isolated prior to transfer to adult services. Data were
collected and analysed on the choice and duration of
therapy, the success of eradication, the time until
P aeruginosa was eradicated and the duration until a new
isolation of P aeruginosa was identiﬁed. The forced expira-
tory volume in 1 s (FEV1) of patients at baseline, before
the ﬁrst P aeruginosa infection, at the time of isolation
and following the completion of AETwas also studied.
Bacteriological examination of sputum
The technique of sputum bacteriological examination
remained unaltered throughout the duration of the
study. Brieﬂy, freshly expectorated sputum specimens
from patients with CF were mixed (1:1) with Sputasol
(Oxoid, UK) and plated onto Columbia blood agar
(Oxoid CM331), supplemented with 5% deﬁbrinated
horse blood, as well as Pseudomonas isolation agar
(Oxoid 559) and incubated prior to examining for
Paeruginosa. All presumptive P aeruginosa isolates were
conﬁrmed phenotypically, at which a Pseudomonas posi-
tive report was issued.10
Patients had sputum examination at median intervals
of 2 months (range 1–6 months) in the 6 months pre-
ceding ﬁrst isolation P aeruginosa. Following ﬁrst isola-
tion, sputum was serially re-examined at median
intervals of 24 days (range 4–154 days) until eradication.
In patients who later reisolated P aeruginosa, sputum was
examined at median intervals of 1 month (range 1–11
months) from eradication until reinfection. In patients
who remained free from P aeruginosa from ﬁrst eradica-
tion, sputum was examined at median intervals of
1 month (range 1–15 months) until the end of the study
period.
Defining successful eradication and new isolation
Eradication was considered to be successful when the
patient did not culture P aeruginosa for at least
12 months, determined as at least three sputum cultures
were performed, each separated by at least 1 month.11
The time to achieve successful eradication of
P aeruginosa was taken to be the time from the start of
therapy until the ﬁrst negative sputum culture was
recorded, after which cultures remained negative for at
least 12 months. The duration until reinfection with
P aeruginosa was determined as the number of months
from the date of successful eradication until the date of
a subsequent P aeruginosa positive respiratory culture.
Lung function
Baseline lung function was taken to be the best FEV1
(%) recorded in the 6 months preceding the ﬁrst
P aeruginosa isolation. FEV1 at the time of culture of
P aeruginosa was taken to be the FEV1 on the date of the
positive sample if recorded and, where not available, the
date closest to the date of positive culture. The best
FEV1 values between 6 and 12 months following the start
of treatment were collected.
Statistical analysis
Comparison between the FEV1 of patients at baseline,
before the ﬁrst P aeruginosa infection, at the time of iso-
lation and following the completion of AET was made
using the paired Student t test. Mean (SD) was used for
data which were normally distributed, and median was
used for data which were not normally distributed.
A p value ≤0.05 was considered to be signiﬁcant.
RESULTS
Twenty patients who met the inclusion criteria were
identiﬁed as isolating P aeruginosa in a respiratory
culture for the ﬁrst time during the study period. One
patient isolated P aeruginosa for the ﬁrst time but was
treated at another centre.
Patient demographics
Figure 1 compares the genetic mutations between the
study group and the total population recorded on the CF
registry. Of the total population on the CF registry, 71% of
F508del homozygotes were infected with P aeruginosa. Of
all patients who were infected with P aeruginosa, almost
half had a F508del homozygous mutation (49.5%).
The median age of the study group was 27 years
(range 18–81 years), compared with 30 years in the
adult CF population. Two of the 20 patients were
F508del homozygous. There were fewer F508del homo-
zygous patients in the study group (10%), compared
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with the adult CF population (36%). There was a
greater proportion of R117H heterozygous patients
within the study group (35%) than in the adult CF
population (15%). The mean baseline FEV1 before ﬁrst
isolate P aeruginosa was 83.34% predicted (95% CI
73.32% to 94.36%).
Eradication therapy
Box 1 outlines AET for each patient during this study.
Ten patients were treated with oral ciproﬂoxacin (10–
20 mg/kg twice daily to a maximum 1000 mg twice daily)
and nebulised colomycin (1 million units twice daily) for
a median duration of 6 weeks (range 2–8 weeks) and
3 months (range 2–3 months), respectively.12 Seven
patients received intravenous antipseudomonal antibio-
tics (median duration 14 days, range 9–14 days). Three of
these patients continued on nebulised therapy after ﬁn-
ishing intravenous antibiotics as their sputum was persist-
ently positive for P aeruginosa. One patient was treated
with inhaled tobramycin and oral ciproﬂoxacin. One
patient received oral ciproﬂoxacin only.
One patient was not started on antipseudomonal
therapy as she was receiving long-term therapy for
Mycobacterium chelonae (clarithromycin, ethambutol and
rifampicin).
Success of eradication therapy
Figure 2 illustrates the patient outcomes of AET.
Successful eradication with ﬁrst-line therapy was
achieved in 15 of 19 treated cases with a negative
sputum culture within 6 weeks of starting treatment, fol-
lowed by at least three negative sputum cultures in the
following 12 months. Six patients continued to isolate
P aeruginosa in sputum samples, following the comple-
tion of the ﬁrst choice therapy. These six patients were
started on further therapies which resulted in successful
eradication in two patients. Therefore, 15 out of 19
treated patients (79%) had successful P aeruginosa eradi-
cation. The median time to eradicate P aeruginosa from
respiratory cultures was 1 month (range 1–6 months).
Chronic infection and P aeruginosa reinfection
Four patients (21%) continued to culture P aeruginosa
and became chronically infected (deﬁned as ≥50% cul-
tures positive in 12 months) despite early treatment and
repeated courses of AET. Ten patients who had been
successfully cleared of P aeruginosa infection following
the ﬁrst isolation later cultured a new isolation within
the study period. The median time from successful
eradication to reinfection with P aeruginosa was
43 months (range 9–68 months). The eradication of sub-
sequent isolations of P aeruginosa was successful in eight
of these patients but two became chronically infected
during the study period. The patient on long-term AET
for M chelonae became chronically infected with
P aeruginosa 11 months after ﬁrst isolation.
By the end of the study period, the patients who did
not reisolate P aeruginosa after eradication had been free
from P aeruginosa for a median of 99 months (range 13–
120 months).
Chronic P aeruginosa infection and associated mortality
Three of 20 patients died within the study period (mor-
tality 15%). One patient died from traumatic injuries in
a road trafﬁc accident 97 months after ﬁrst isolating
P aeruginosa. One patient became chronically infected
with P aeruginosa after ﬁrst isolation and died 84 months
later from complications of the lower respiratory tract
infection. The third patient died from respiratory and
hepatic failure 65 months after ﬁrst isolation but was not
chronically infected with P aeruginosa.
Lung function
At the time patients isolated P aeruginosa, there was a
mean (SD) fall from baseline FEV1 82.4 (24.0)% to 77.3
(26.3)% predicted (p=0.002). After completion of AET,
there was improvement in mean FEV1 to 81.2 (23.9)%
Box 1 Choice of antipseudomonal eradication therapy
Eradication therapy (median duration)
Oral ciprofloxacin (6 weeks) and nebulised colomycin
(3 months)—10 cases
Intravenous antibiotic therapy (14 days)—7 cases
Ceftazidime and tobramycin (3 cases)
Ceftazidime and amikacin plus nebulised colomycin
Ceftazidime, gentamicin and meropenem plus nebulised
colomycin
Aztreonam and tobramycin
Piperacillin–tazobactam and tobramycin
Other therapy—2 cases
Nebulised tobramycin and oral ciprofloxacin
Oral ciprofloxacin alone.
No therapy—1 case
Figure 1 Comparison breakdown of genetic mutations
between the study patients and all adult patients with cystic
fibrosis on the registry.
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predicted (p=0.02). After 12 months, there was no sig-
niﬁcant deterioration in lung function compared with
baseline (from 82.4% to 82.3%, p=0.91). Additionally,
there was no signiﬁcant difference between patients who
developed chronic P aeruginosa infection (mean FEV1%
predicted at: baseline 83.1%; after AET 83.9%) com-
pared with those successfully eradicated (mean FEV1%
predicted at: baseline 82.0%; after AET 81.5%) after
12 months (p=0.63)
The use of intravenous antipseudomonal therapy as
the ﬁrst-line AET was consistent with these patients
being more clinically unwell at the time of P aeruginosa
infection, as evidenced by the greater fall in the mean
FEV1 from baseline. The patients treated with intraven-
ous therapies had a fall in mean FEV1% predicted of
7.9% (from 80.9% to 73.0%) compared with 3.3% for
those treated with nebulised plus oral therapy (83.3–
80.0%), although this was not signiﬁcant (p=0.16)
Impact of mutations
Patients with the F508del homozygous mutation dis-
played a greater fall in FEV1% predicted (from 81.2% to
65.3%) compared with those who were non-F508del
homozygous (from 82.5% to 78.6%) after isolating
P aeruginosa for the ﬁrst time (p=0.007). Both F508del
homozygous patients failed to eradicate ﬁrst isolate
P aeruginosa and became chronically infected.
Patients with the R117H mutation displayed a smaller
fall in FEV1% predicted (from 96.2% to 93.2%)
compared with those without the R117H mutation
(from 78.9% to 73.3%), although this was not signiﬁcant
(p=0.46). All four patients with the R117H mutation
had successful eradication of the ﬁrst isolate of
Paeruginosa and did not become chronically infected.
DISCUSSION
Comparing P aeruginosa eradication in adults
and children
The recognition of chronic P aeruginosa infection as a
poor prognostic factor for patients with CF has prompted
a number of clinical trials into determining the optimum
AET.2 Most of these trials report median ages in the
paediatric range, which is consistent with ﬁrst-time
P aeruginosa isolation occurring most often in childhood.
This study was a review of ﬁrst isolate P aeruginosa eradica-
tion in adults (median age 27 years) which sought to
compare eradication rates with children.
The success of eradication in this study (79%) is com-
parable to the range found in the published literature
among younger populations (68–93%).6–8 The median
time to eradicate was 1 month (range 1–6 months),
which is similar to that reported in paediatric studies.
The median time until reinfection with P aeruginosa
(median 43 months) also compares favourably with the
previous studies in children (5–26 months). Therefore,
this study suggests that AET of ﬁrst isolate P aeruginosa is
equally effective in adults and children.13
Figure 2 Chart showing outcomes of antipseudomonal therapy of study population. CF, cystic fibrosis; NI, Northern Ireland.
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Patients who are F508del homozygous are less likely to
reach adulthood without P aeruginosa infection than
those with other mutations.14 This is the most likely
explanation for the notable difference in the proportion
of patients who were F508del homozygous in our study
population (10%) compared with the total population
on the CF registry (36%). It is also possible that AET is
more effective in patients with mutations associated with
residual chloride function. This is consistent with the
successful rates of eradication in patients with the
R117H mutation seen in this study.
Comparing choice of antipseudomonal therapy
Previous trials into AETof P aeruginosa have varied greatly
in the study design and the choice of the eradication
regime. In 2010, the Cochrane Collaboration produced a
review of antibiotic strategies for P aeruginosa eradication
in patients with CF.13 It found that most studies had
focused on inhaled tobramycin versus placebo, with one
study comparing inhaled tobramycin with inhaled colistin
and oral ciproﬂoxacin. It concluded that, although both
antibiotic regimes were better than placebo, there was
insufﬁcient evidence to determine which was superior.
Later studies by Taccetti et al15 and Proesmans et al8
found that eradication success was very similar between
the two regimes.
The value of intravenous antibiotics in P aeruginosa
eradication is still under investigation. Some trials have
reported economic beneﬁts and reduced lung inﬂam-
mation in the use of systemic antibiotics.16 17 The
TORPEDO-CF trial is currently underway to establish its
comparative eradication efﬁcacy.18 In our study, intraven-
ous therapy was generally reserved for patients who were
more unwell, as demonstrated by a greater reduction in
FEV1 from baseline. However, there was no standardised
method to determine what degree of reduction war-
ranted systemic antibiotics over other regimes. This may
be a useful research focus for future studies.
There are two main explanations for the wide variety
of AETs reported in this study. The ﬁrst is the frequency
of patients being switched to alternative agents following
the failure or adverse reactions on ﬁrst-line treatments.
The second and more signiﬁcant reason is the develop-
ing evidence base for different ﬁrst-line regimes during
the 13-year study period (1999–2012). Nebulised tobra-
mycin has the best reported eradication success,6 but
since this was established late in the study period only a
few patients received it.
Decisions over AET can be further complicated by
coinfection, as demonstrated by the patient who isolated
P aeruginosa while on long-term therapy for M chelonae.
The complex microbial community found in airways of
patients with CF is a current focus of research as the
clinical signiﬁcance of many pathogens is not well
understood.19 P aeruginosa and non-tuberculous myco-
bacterium are established as pathogenic in CF,2 although
little data are available to compare their associated mor-
bidity. In this case, no change was made to the patient’s
therapy as it was determined that the risks of interfering
with non-tuberculosis mycobacterium AET outweighed
the beneﬁts of attempting P aeruginosa eradication.
Comparing efficacy of antipseudomonal therapy
It is difﬁcult to compare efﬁcacy with previous studies as
there are signiﬁcant variations in patient demographics,
choice and duration of therapy and measures of success.
We observed an eradication success of ﬁrst P aeruginosa
isolate of 79%. This compares well to Taccetti et al7 who
achieved 81% eradication with oral ciproﬂoxacin and
nebulised colomycin (mean age 8.9 years). However, the
ELITE trial found that tobramycin inhaled for 28 days
resulted in 93% eradication after 1 month, with 66%
remaining free of P aeruginosa after 27 months (mean
age 8.7 years).6 There were too few patients on inhaled
tobramycin in this study to compare efﬁcacy.
Studies by Hansen et al12 and Schelstraete et al20 found
that a short P aeruginosa free interval following AET may
predict chronic infection. We observed a 66% reinfec-
tion rate of P aeruginosa in successfully eradicated
patients. The median time to reinfection was 43 months.
Taccetti et al7 reported 51% (24 patients) becoming rein-
fected with a median recurrence interval of 18 months
over a 9-year period. The increased P aeruginosa free
period and incidence of reinfection in our study may be
attributable to the longer study period of 13 years.
Study limitations
The study is limited by the small number of adult
patients isolating P aeruginosa for the ﬁrst time during
the period of study (20). In addition, there was a signiﬁ-
cant variety in choice and duration of antipseudomonal
therapies. This study was a chart review which depends
largely on comprehensive and accurate documentation
of therapies and outcomes over a 13-year period.
Therefore, it is difﬁcult to reliably establish the efﬁcacy
of varying treatments retrospectively in a small patient
population.
CONCLUSION
Even with its limitations, this study demonstrates that
aggressive AET of ﬁrst-time P aeruginosa infection in
adults at this centre is successful in the majority of
patients and is of similar efﬁcacy to the reported success
in younger, mainly paediatric populations. Similar to
previous studies, there is evidence that despite successful
eradication of the ﬁrst isolation, the reinfection of
P aeruginosa is common. However, the eradication of
recurrent P aeruginosa can still be successful among the
adult CF population and can prevent chronic infection
in the majority of adult patients.
The number of patients with CF entering adult care with
no history of P aeruginosa infection is increasing and the
need for AET in adults will become more frequent.5 The
results of the TORPEDO trial are awaited to determine
the role and efﬁcacy of intravenous antipseudomonal
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therapy. Further research should include a multicentre
prospective study to establish optimum AET in ﬁrst-time
P aeruginosa isolation in adult patients with CF.
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